Open access · OA
via Europe PMC
Sleep-neuroinflammation interactions in Alzheimer's disease: a systematic review of biomarker pathways.
Cordella A, Bruschetti-Thomi A, Sacco L, Liguori C.
Frontiers in aging neuroscience · 2026
Abstract
Although sleep disturbances are increasingly associated with Alzheimer's disease (AD), the mechanistic interplay between sleep physiology, neuroinflammation and AD-related pathology is not fully understood. The question of whether disrupted sleep contributes to neurodegeneration or merely reflects early pathological processes is still being debated. In accordance with PRISMA-2020 guidelines, we conducted a systematic review to synthesize the current evidence linking objectively measured sleep alterations, glial activation and AD-related outcomes. A comprehensive search of PubMed, Scopus, EMBASE and Web of Science (January 2000 - June 2026) identified 40 original studies that met the predefined inclusion criteria. These studies included objective sleep assessments (polysomnography, electroencephalography, actigraphy, or experimental sleep manipulation), direct evaluations of neuroinflammatory or glial markers, and assessments of amyloid-<i>β</i> (Aβ), tau pathology, neurodegeneration and cognition. Human studies indicate that slow-wave sleep impairment, sleep fragmentation, and REM sleep dysregulation are linked to neuroinflammation and AD-related pathology. Further mechanistic insights come from experimental animal and translational studies, which show that sleep deprivation or disruption may enhance microglial activation, astrocytic reactivity, and the accumulation of AD-related proteins. However, limited prior work has integrated evidence from sleep physiology, central neuroinflammatory measures, and multimodal AD biomarkers in humans. The available evidence supports a biologically plausible, potentially bidirectional relationship between sleep disruption and AD pathology, while highlighting important gaps in translation. Further longitudinal and interventional investigations are required to clarify causality and determine whether targeting sleep physiology could meaningfully influence disease trajectories.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3389/fnagi.2026.1854872
- Canonical
- link ↗
- Fetched
- 2026-10-13 MST
Cite this
APA
A, C., A, B., L, S., & C., L. (2026). Sleep-neuroinflammation interactions in Alzheimer's disease: a systematic review of biomarker pathways. <em>Frontiers in aging neuroscience</em>. https://doi.org/10.3389/fnagi.2026.1854872
Vancouver
A C, A B, L S, C. L. Sleep-neuroinflammation interactions in Alzheimer's disease: a systematic review of biomarker pathways. Frontiers in aging neuroscience. 2026. doi:10.3389/fnagi.2026.1854872.
BibTeX
@article{cordella2026Sleepn,
title = {Sleep-neuroinflammation interactions in Alzheimer's disease: a systematic review of biomarker pathways.},
author = {Cordella A and Bruschetti-Thomi A and Sacco L and Liguori C.},
journal = {Frontiers in aging neuroscience},
year = {2026},
doi = {10.3389/fnagi.2026.1854872},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Current Issues in Molecular Biology 2025
Open access · CC-BY
Protein Misfolding and Aggregation as a Mechanistic Link Between Chronic Pain and Neurodegenerative Diseases
Proteomes 2016
Open access · CC-BY
The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease
Journal of Krishna Institute of Medical Sciences University 2026
Open access · CC-BY
Effects of senolytic interventions on cognitive outcomes in animal models of aging and neurodegenerative disease: A systematic review
Current topics in behavioral neurosciences 2016
Open access · CC-BY
Orexin and Alzheimer’s Disease
Stem Cell Research & Therapy 2025
Open access · CC-BY
Targeting cellular senescence in progenitor cells as a strategy to enhance bone regeneration by cell therapies: a systematic review of pre-clinical investigations
Aging and disease 2026
Citation only